Extending Excellence
from Samples
to Experience
Combining GCLP-compliant precision analysis with advanced IT systems,
we unlock the full value of biospecimens and deliver innovative analytical solutions.
Redefining Clinical
Lab Experience
Streamlining complex clinical operations and redefining the client
experience through transparent,data-driven services
From Korea
to the Global Trial
Empowering global clinical development with world-class
analytical capabilities and extensive clinical trial expertise.
Subscribe to Newsletter
R&D for Extended
Clinical Insights
U2XLab develops and validates methods optimized for every stage of drug development,
With a specialized focus on highly complex domains.
Delivering globally compliant data and enhanced clinical insights
By integrating LC-MS/MS and immunoassay platforms with our RVDS-based IT infrastructure.
Delivering customized analytical strategies optimized for each drug candidate's specific profile, utilizing a diverse suite of platforms such as LC‑MS/MS, immunoassays, flow cytometry, and qPCR
Test Portfolio
Offering a comprehensive analytical portfolio dedicated to clinical trials, including PK/PD, ADA, biomarker analysis, and PBMC isolation
Biomarker Strategies
Establishing tailored analytical methods that reflect the unique profiles of biomarkers across major therapeutic areas, including Oncology, Immunology, and CNS.
A New Paradigm in Clinical Trials
U2XLab is a GCLP-certified laboratory that pioneered South Korea's first Central Lab services for clinical trials across Asia. Since our founding in 2012, we have supported the entire clinical trial lifecycle through analytical services and quality management that meet global standards.
Latest NEWS
_20a16.png)
Meet U2XLab at KIC 2026! 🔬
_ee9fd.png)
Meet U2XLab at BIO JAPAN 2026! 🏯
---V1 3_ff3fa.jpg)
[MaekyungHealth] Six in Ten Koreans Have Just 0–2 Probiotic Strains Recognized by the Ministry of Food and Drug Safety
 1_1d4b5.jpg)
[ChosunBiz] U2Biome Publishes Gut Microbiome Analysis Results, Confirming Strain Changes Following Personalized Probiotic Intake
[NewsWire] U2Bio Begins Full-Scale Management of SML Meditree as New CEO Hyuk-sung Jin Takes Office and Company Rebrands as U2XLab
